This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Renvela (Tablet or Powder)

Sanofi

Drug Names(s): sevelamer carbonate

Description: Sevelamer carbonate is a second-generation formulation of Renagel (sevelamer hydrochloride). Taken with meals, sevelamer carbonate binds to dietary phosphate in the gut and thus prevents its absorption. Genzyme is developing Renvela in both tablet and powder form.

Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.


Renvela (Tablet or Powder) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug